Core Viewpoint - The credit rating agency has assigned a stable outlook to Guangzhou Jiete Biological Filtration Co., Ltd., reflecting its solid operational foundation and stable cooperation with global life science industry leaders, despite facing certain risks related to capacity digestion and reliance on overseas clients [3][6][16]. Company Overview - Guangzhou Jiete Biological Filtration Co., Ltd. specializes in the research, production, and sales of cell culture and related liquid handling life science consumables, maintaining a strong R&D capability in the field [3][5]. - The company has a credit rating of A+ with a stable outlook, indicating a good financial position and manageable debt levels [3][6]. Financial Performance - As of March 2025, the company's total assets reached 17.05 billion, with equity attributable to shareholders at 12.06 billion and total debt at 3.70 billion [3][4]. - The company's revenue for 2024 was 5.59 billion, with a net profit of 0.73 billion, showing a recovery in both revenue and profit scales [3][4]. - The cash-to-short-term debt ratio was notably high at 104.08, indicating strong liquidity [4][5]. Market Position - The company holds a significant position in the domestic supply chain for biological laboratory consumables, with stable cooperation with high-quality clients [6][9]. - The global life science industry giants continue to be major clients, ensuring a steady revenue stream [6][16]. Industry Environment - The life science industry in China has seen rapid growth in research funding, increasing from 59.7 billion in 2017 to 141.5 billion in 2023, with a compound annual growth rate of 15.5% [9][10]. - The market for biological laboratory consumables is projected to grow from 16.49 billion in 2022 to 23.42 billion in 2024, with a compound annual growth rate of 19.17% [10][11]. Risks and Challenges - The company faces uncertainties in capacity digestion and is highly dependent on overseas clients, with 66.13% of its revenue coming from international sales [5][16]. - The reliance on imported raw materials poses risks related to price fluctuations and geopolitical factors, which could adversely affect the company's performance [5][16]. Future Outlook - The credit rating agency maintains a stable outlook for the company, citing its strong cash position and low debt levels as positive indicators for future performance [6][9]. - The company is expected to continue benefiting from its established relationships with global life science leaders, although it must navigate the challenges posed by market competition and external economic factors [6][16].

Group 1 - The company's credit rating remains at A+ with a stable outlook for both the company and its convertible bonds [1][2] - The credit rating agency Zhongzheng Pengyuan conducted a follow-up credit rating for the company on June 26, 2025, confirming the ratings [2] - The previous credit rating was also A+ with a stable outlook, assessed on June 26, 2024 [1][2] Group 2 - The follow-up rating report was published on the Shanghai Stock Exchange website on the same day as the rating [2]

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-038 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于"洁特转债"跟踪信用评级结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 前次债券评级：公司主体信用等级为 A+，评级展望为"稳定"，"洁特 转债"的信用等级为 A+。 本次债券评级：公司主体信用等级为 A+，评级展望为"稳定"，"洁特 转债"的信用等级为 A+。 广州洁特生物过滤股份有限公司董事会 2025 年 6 月 28 日 2 根据《上市公司证券发行注册管理办法》《上海证券交易所科创板股票上市 规则》等有关规定，广州洁特生物过滤股份有限公司（以下简称"公司"）委托 信用评级机构中证鹏元资信评估股份有限公司（以下简称"中证鹏元"）对公司 于 2022 年 6 月向不特定对象发行的可转换公司债券（以下简称"洁特转债"） 进行了跟踪信用评级。 公司前次主体信用评级结果为 A+， ...

广州洁特生物过滤股份有限公司 相关债券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【397】号 01 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未经 ...

Core Viewpoint - The company, Guangzhou Jiete Biological Filtration Co., Ltd., is implementing a differentiated dividend distribution plan for the year 2024, which is based on the number of shares available after accounting for shares repurchased and held in a special account [1][2][5]. Group 1: Reasons for Differentiated Dividend - The differentiated dividend is a result of the company's decision to repurchase shares using its own or raised funds, with a total repurchase amount between RMB 20 million and RMB 40 million, and a maximum repurchase price of RMB 19.36 per share [1][2]. - The repurchased shares will not participate in profit distribution, leading to the need for a differentiated dividend distribution plan [2][3]. Group 2: Dividend Distribution Plan - The company plans to distribute a cash dividend of RMB 0.73 per 10 shares (including tax) to all shareholders based on the total share capital minus the repurchased shares [2][3]. - The actual number of shares participating in the distribution is 137,632,306 shares, calculated from the total share capital of 140,363,220 shares after deducting the repurchased shares [3][4]. Group 3: Calculation Basis for Differentiated Dividend - The cash dividend per share is calculated based on the adjusted total share capital, and the reference price for ex-dividend trading is determined using the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio) [3][4]. - The impact of the differentiated dividend on the ex-dividend reference price is minimal, with an absolute value change of less than 1% [4]. Group 4: Verification Opinion - The sponsoring institution, Minsheng Securities, confirms that the differentiated dividend distribution complies with relevant laws and regulations, ensuring no harm to the interests of the company and all shareholders [5][6].

Core Viewpoint - The company announced an adjustment to the conversion price of its convertible bonds due to the implementation of the 2024 annual profit distribution plan, which includes a cash dividend of 0.73 yuan per 10 shares [1][2][4]. Summary by Sections Announcement of Adjustment - The conversion price of "洁特转债" will be adjusted from 48.02 yuan per share to 47.95 yuan per share, effective from July 2, 2025 [1][4]. - The trading of "洁特转债" will be suspended from June 24, 2025, until the equity registration date of July 1, 2025, and will resume on July 2, 2025 [1][4]. Basis for Adjustment - The adjustment is based on the resolution passed at the 2024 annual general meeting, which approved a cash dividend distribution of 0.73 yuan per 10 shares, with no stock increases or bonus shares [1][2][4]. - The total number of shares after excluding repurchased shares is 140,363,220, with 2,730,914 shares repurchased [4]. Calculation of Adjustment - The cash dividend per share is calculated as approximately 0.0716 yuan, leading to the new conversion price being calculated as follows: P1 = P0 - D, where P0 is the old conversion price and D is the cash dividend [4]. - The formula for adjusting the conversion price is provided, detailing how various corporate actions affect the conversion price [2][4]. Other Information - Investors seeking more details about "洁特转债" can refer to the company's prospectus published on June 24, 2022 [5].

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-037 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 调整前转股价：48.02 元/股 调整后转股价：47.95 元/股 转股价格调整起始日期：2025 年 7 月 2 日 日起至实施权益分派股权登记日期间，因可转债转股/回购股份/股权激励授予股份 回购注销/重大资产重组股份回购注销等致使公司总股本发生变动的，或者回购股 份数发生变动的，公司拟维持每股分配比例不变，相应调整分配总额。 关于实施 2024 年年度权益分派时 调整"洁特转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因实施 2024 年年度权益分派,本公司的相关证券停复牌情况如下：权益分派公 告前一交易日（2025 年 6 月 24 日）至权益分派股权登记日（2025 年 7 月 1 日） 期间，"洁特转债"将停止转股，于 2025 年 7 月 ...

民生证券股份有限公司 关于广州洁特生物过滤股份有限公司 差异化分红事项的核查意见 民生证券股份有限公司（以下简称"保荐机构"）作为广州洁特生物过滤股 份有限公司（以下简称"洁特生物"或"公司"）2022 年向不特定对象发行可转 换公司债券的保荐机构，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》（以下简称"《证券法》"）《上海证券交易所上市公司 自律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章及其他规 范性文件相关规定，对洁特生物 2024 年度利润分配所涉及的差异化分红（以下 简称"本次差异化分红"）相关事项进行了审慎核查，并出具核查意见如下： 一、本次差异化分红原因 2024 年 2 月 18 日，公司第四届董事会第六次会议审议通过《关于以集中竞 价交易方式回购公司股份的议案》，同意公司使用自有资金或自筹资金以集中竞 价交易方式回购公司人民币普通股（A 股）股票，用于员工持股计划或股权激励， 以及用于维护公司价值及股东权益，回购价格不超过人民币 19.36 元/股（含）， 回购资金总额不低于人民币 2,000 万元（含）且不超过人民币 4,000 万元（ ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-036 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 二、 分配方案 1. 发放年度：2024年年度 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.073元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/1 | 2025/7/2 | 2025/7/2 | 一、 通过分配方案的股东大会届次和日期 2024年年度权益分派实施公告 本次利润分配方案已经广州洁特生物过滤股份有限公司（以下简称"公司"） 2025 年 5 月 7 日的2024年年度股东大会审议通过。 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东 （公司回购专用证券账户除外）。 根据《 ...

Core Viewpoint - The announcement details the interest payment schedule for the company's convertible bonds, including key dates and interest rates, ensuring compliance with regulatory requirements [1][2][3]. Group 1: Convertible Bond Issuance Overview - The company issued 4.4 million convertible bonds on June 28, 2022, with a total fundraising amount of 440 million RMB [1][2]. - The bonds have a six-year term, maturing on June 27, 2028, and feature a tiered interest rate structure, starting at 0.30% in the first year and reaching 2.00% by the sixth year [1][2]. Group 2: Interest Payment Details - The third interest payment will occur on June 30, 2025, covering the period from June 28, 2024, to June 27, 2025, with a coupon rate of 1.00% [3][4]. - The interest amount payable per bond is 1.00 RMB (before tax) for each bond with a face value of 100 RMB [3][5]. Group 3: Payment Schedule and Methods - The bondholders' registration date for interest payment is June 27, 2025, with the ex-dividend date also set for June 30, 2025 [3][4]. - The company has appointed China Securities Depository and Clearing Corporation Limited Shanghai Branch to handle the interest payment process [4][6]. Group 4: Tax Implications for Investors - Individual investors are subject to a 20% tax on interest income, resulting in a net payment of 0.80 RMB per bond after tax [5]. - Non-resident investors are exempt from corporate income tax on bond interest income until December 31, 2025, under specific conditions [5].